Schmitz, Gerd and Aslanidis, Charalampos and Lackner, Karl J. (2001) Pharmacogenomics: implications for laboratory medicine. CLINICA CHIMICA ACTA, 308 (1-2). pp. 43-53. ISSN 0009-8981, 1873-3492
Full text not available from this repository.Abstract
Pharmacogenomics deals with the interactions of individual genetic constitution with drug therapy. It has potentially far reaching consequences for drug development and future treatment strategies, but also for clinical in vitro diagnostics. With increasing knowledge about interactions between genes and drug treatment, there will be an equally increasing demand for rapid and reliable diagnostic tests prior to the institution of therapy. In fact. it is very likely that pharmacogenetic tests will make up a significant proportion of total molecular biology testing in the coming years. Therefore, this review focuses on the implications of pharmacogenomics on the clinical laboratory. (C) 2001 Elsevier Science B.V. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | SINGLE-NUCLEOTIDE POLYMORPHISM; DIAGONAL GEL-ELECTROPHORESIS; MASS-SPECTROMETRY; RECEPTOR; GENE; SYSTEM; ASSAY; ASSOCIATION; GENOTYPE; MUTATION; pharmacogenomics; laboratory medicine; diagnostics |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Klinische Chemie und Laboratoriumsmedizin |
| Depositing User: | Petra Gürster |
| Date Deposited: | 14 May 2021 07:00 |
| Last Modified: | 14 May 2021 07:00 |
| URI: | https://pred.uni-regensburg.de/id/eprint/41362 |
Actions (login required)
 |
View Item |
